Fortress Biotech: Q1 Earnings Snapshot
Fortress Biotech: Q3 Earnings Snapshot
Fortress Biotech: Q2 Earnings Snapshot
Fortress Biotech: Q1 Earnings Snapshot
Fortress Biotech: Q3 Earnings Snapshot
MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on...
Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021 DFD-29 Phase 3 studies 45% enrolled to date; 9 additional...
Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor in clinical development at Fortress’ subsidiary company, UR-1 Therapeutics ...
SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage...
SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical...